Tirzepatide: What the Research Shows About the GIP/GLP-1 Dual-Agonist Peptide

Tirzepatide is one of the most-studied dual-receptor peptides in metabolic research. This guide summarizes what the published scientific literature has examined about tirzepatide, its molecular profile, and how it is handled in a research setting. It is written for researchers and is not medical guidance.

What is tirzepatide?

Tirzepatide (developmental code LY3298176; CAS 2023788-19-2; molecular formula C₂₂₅H₃₄₈N₄₈O₆₈; molar mass ≈ 4813 g/mol) is a synthetic 39-amino-acid peptide engineered as a dual agonist that activates two receptors: the GIP receptor and the GLP-1 receptor. Its structure is based on the GIP sequence and includes a fatty di-acid moiety that extends its duration of action. The active compound has been approved by regulators as a prescription medicine, but the material supplied here is intended strictly for laboratory research — it is not the pharmaceutical product and is not for human use.

Research-use note: Tirzepatide is supplied strictly for laboratory research. It is not a supplement and not for human or animal consumption. Nothing below describes or endorses human use.

How tirzepatide works (the mechanism studied)

Tirzepatide is characterized in the literature as a dual GIP and GLP-1 receptor agonist. Research has examined how simultaneous activation of both incretin pathways influences insulin secretion, insulin sensitivity, and body-weight regulation in study models, an effect investigated as potentially greater than activation of the GLP-1 receptor alone (reviewed in Tan & Hinson, 2022).

What researchers have studied

The published record on tirzepatide consists largely of clinical-trial data. The most-cited studies include:

Type 2 diabetes research — Frías et al. (New England Journal of Medicine, 2021), the SURPASS-2 trial comparing tirzepatide with semaglutide on glycemic endpoints.
Obesity research — the SURMOUNT-2 trial (The Lancet, 2023) examined body-weight endpoints in participants with type 2 diabetes.

These findings belong to the published research record and do not represent approved or validated uses of the research compound sold here.

Tirzepatide compared with other incretin peptides

Researchers often group these compounds by how many receptors they engage:

Single agonist (GLP-1 only)
Dual agonist (GIP + GLP-1) — tirzepatide
Triple agonist (GIP + GLP-1 + glucagon) — see our retatrutide research guide

Handling and reconstitution in the laboratory

Tirzepatide is typically supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (General lab-handling notes, not usage instructions.)

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.

Explore tirzepatide and related research peptides

Tirzepatide 20mg — verified CAS, formula, and specifications
Retatrutide (GLP-3) — GIP/GLP-1/glucagon triple agonist
Bacteriostatic Water 30ml — reconstitution diluent

References

Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. PubMed
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PubMed
Tan T, Hinson J. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist. 2022. PubMed